Circassia Pharmaceuticals Plc (CIR):企業の財務・戦略的SWOT分析

◆英語タイトル:Circassia Pharmaceuticals Plc (CIR) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C4813
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Circassia Pharmaceuticals Plc (CIR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease. The company had several inhaled medicines in pipeline intended for the treatment chronic obstructive pulmonary disease (COPD), which include single and combination dose products. The company offers its products to COPD and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Pharmaceuticals Plc Key Recent Developments

Apr 24,2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017
Feb 13,2018: Circassia Announces Changes to its Board of Directors
Nov 29,2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis
Sep 27,2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017
Apr 25,2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Circassia Pharmaceuticals Plc – Key Facts 6
Circassia Pharmaceuticals Plc – Key Employees 7
Circassia Pharmaceuticals Plc – Key Employee Biographies 8
Circassia Pharmaceuticals Plc – Major Products and Services 9
Circassia Pharmaceuticals Plc – History 10
Circassia Pharmaceuticals Plc – Company Statement 11
Circassia Pharmaceuticals Plc – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Circassia Pharmaceuticals Plc – Business Description 15
Business Segment: Niox Segment 15
Overview 15
Performance 15
Business Segment: Respiratory segment 15
Overview 15
Performance 15
Business Segment: US AZ collaboration 15
Overview 15
Performance 15
Geographical Segment: Asia Pacific 16
Performance 16
Geographical Segment: EU 16
Performance 16
Geographical Segment: Rest of World 16
Performance 16
Geographical Segment: US 16
Performance 16
R&D Overview 16
Circassia Pharmaceuticals Plc – SWOT Analysis 17
SWOT Analysis – Overview 17
Circassia Pharmaceuticals Plc – Strengths 17
Circassia Pharmaceuticals Plc – Weaknesses 18
Circassia Pharmaceuticals Plc – Opportunities 19
Circassia Pharmaceuticals Plc – Threats 20
Circassia Pharmaceuticals Plc – Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios – Capital Market Ratios 22
Financial Ratios – Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Circassia Pharmaceuticals Plc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Apr 24, 2018: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2017 31
Feb 13, 2018: Circassia Announces Changes to its Board of Directors 32
Nov 29, 2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis 33
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 34
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 35
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 36
Section 6 – Appendix 37
Methodology 37
Ratio Definitions 37
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Circassia Pharmaceuticals Plc, Key Facts 6
Circassia Pharmaceuticals Plc, Key Employees 7
Circassia Pharmaceuticals Plc, Key Employee Biographies 8
Circassia Pharmaceuticals Plc, Major Products and Services 9
Circassia Pharmaceuticals Plc, History 10
Circassia Pharmaceuticals Plc, Subsidiaries 13
Circassia Pharmaceuticals Plc, Key Competitors 21
Circassia Pharmaceuticals Plc, Ratios based on current share price 22
Circassia Pharmaceuticals Plc, Annual Ratios 23
Circassia Pharmaceuticals Plc, Annual Ratios (Cont...1) 24
Circassia Pharmaceuticals Plc, Interim Ratios 26
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Circassia Pharmaceuticals Plc, Recent Deals Summary 30
Currency Codes 37
Capital Market Ratios 37
Equity Ratios 38
Profitability Ratios 38
Cost Ratios 39
Liquidity Ratios 39
Leverage Ratios 40
Efficiency Ratios 40

List of Figures
Circassia Pharmaceuticals Plc, Performance Chart (2013 - 2017) 25
Circassia Pharmaceuticals Plc, Ratio Charts 27
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Circassia Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

★海外企業調査レポート[Circassia Pharmaceuticals Plc (CIR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Evox Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Evox Therapeutics Ltd (Evox Therapeutics) is a biotechnology company focused on harnessing and engineering the natural delivery capabilities of exosomes, to develop novel medicines for various diseases. Its development pipeline is focused in the therapeutic areas of inflammatory, immune dise …
  • Impax Laboratories Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous sy …
  • Cape plc:企業の戦略・SWOT・財務情報
    Cape plc - Strategy, SWOT and Corporate Finance Report Summary Cape plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Shangri-La Hotels (Malaysia) Berhad:戦略・SWOT・企業財務分析
    Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Mitteldeutsche Braunkohlengesellschaft mbH:企業の戦略的SWOT分析
    Mitteldeutsche Braunkohlengesellschaft mbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • SELEX Galileo Inc.:企業の戦略・SWOT・財務分析
    SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report Summary SELEX Galileo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Nobelpharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary NobelPharma Co Ltd (NobelPharma) is a pharmaceutical company that develops medicines for rare diseases and unmet medical needs. The company’s pipeline products include NPC-09, NPC-12, NPC-15, NPC-16, NPC-17 and NPC-18. It offers products in the therapeutic areas of oncology, metabolic diseas …
  • Aurigene Discovery Technologies Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Aurigene Discovery Technologies Ltd (Aurigene), a subsidiary of Dr. Reddy's Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns inte …
  • BillerudKorsnas AB:企業の戦略・SWOT・財務情報
    BillerudKorsnas AB - Strategy, SWOT and Corporate Finance Report Summary BillerudKorsnas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Capricor Therapeutics Inc (CAPR):製薬・医療:M&Aディール及び事業提携情報
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Insulet Corp (PODD):医療機器:M&Aディール及び事業提携情報
    Summary Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes insulin management systems for diabetic patients. Its OmniPod insulin management system is a continuous insulin delivery system for insulin dependent diabetic s. Omnipod system consists of a dispos …
  • Duke Energy Carolinas LLC:企業の戦略的SWOT分析
    Duke Energy Carolinas LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Breg Inc:医療機器:M&Aディール及び事業提携情報
    Summary Breg Inc (Breg) is a medical device company that manufactures and distributes sports medicine and rehabilitation products. The company offers products such as knee braces, cold therapy, dvt prophylaxis, hip bracing, shoulder bracing, fracture bracing, elbow wrist bracing, spine bracing, foot …
  • Prevas AB (PREV B):企業の財務・戦略的SWOT分析
    Prevas AB (PREV B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Voltalia SA (VLTSA):企業の財務・戦略的SWOT分析
    Voltalia SA (VLTSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Gurit Holding AG (GUR):企業の財務・戦略的SWOT分析
    Gurit Holding AG (GUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Tata Teleservices (Maharashtra) Ltd (TTML):企業の財務・戦略的SWOT分析
    Tata Teleservices (Maharashtra) Ltd (TTML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Parkway Properties Inc:企業のM&A・事業提携・投資動向
    Parkway Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Parkway Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Nippon Paper Industries Co., Ltd.:戦略・SWOT・企業財務分析
    Nippon Paper Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Paper Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆